|
GRHL2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.79280043535834E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.23300000104609E-08 |
| Normal-vs-Stage2 |
9.75380000000081E-05 |
| Normal-vs-Stage3 |
1.40180000052226E-07 |
| Normal-vs-Stage4 |
2.32370000019522E-07 |
| Stage1-vs-Stage2 |
8.786000E-01 |
| Stage1-vs-Stage3 |
2.586400E-01 |
| Stage1-vs-Stage4 |
1.910790E-01 |
| Stage2-vs-Stage3 |
5.269400E-01 |
| Stage2-vs-Stage4 |
4.496800E-01 |
| Stage3-vs-Stage4 |
7.994600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.24889998343036E-09 |
| Normal-vs-AfricanAmerican |
2.256500E-02 |
| Normal-vs-Asian |
3.51210000000268E-05 |
| Caucasian-vs-AfricanAmerican |
2.023000E-01 |
| Caucasian-vs-Asian |
8.733800E-01 |
| AfricanAmerican-vs-Asian |
3.216600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.06730000182642E-08 |
| Normal-vs-Female |
7.01759994559126E-09 |
| Male-vs-Female |
1.174600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.14100000003781E-07 |
| Normal-vs-Age(41-60Yrs) |
7.30160000239621E-08 |
| Normal-vs-Age(61-80Yrs) |
4.45740000021289E-07 |
| Normal-vs-Age(81-100Yrs) |
2.761900E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.583200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.423400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.141700E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.036000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.777600E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.601900E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.743600E-02 |
| Classical-VS-Follicular |
5.350400E-02 |
| Classical-VS-Other |
6.266800E-01 |
| Classical-VS-Normal |
1.9318599999929E-05 |
| Tall-VS-Follicular |
6.860000E-01 |
| Tall-VS-Other |
6.916600E-01 |
| Tall-VS-Normal |
4.8090000004386E-07 |
| Follicular-VS-Other |
8.807400E-01 |
| Follicular-VS-Normal |
1.22959999959704E-07 |
| Other-VS-Normal |
3.438000E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.44669999710712E-08 |
| Normal-vs-N1 |
4.46939999454443E-08 |
| N0-vs-N1 |
1.466440E-01 |
|
|
